{"id":1214,"date":"2023-03-30T14:11:57","date_gmt":"2023-03-30T13:11:57","guid":{"rendered":"http:\/\/molecularhealth.com\/eu\/ressourcen\/"},"modified":"2025-11-24T15:00:55","modified_gmt":"2025-11-24T15:00:55","slug":"ressourcen","status":"publish","type":"page","link":"https:\/\/molecularhealth.com\/eu\/de\/ressourcen\/","title":{"rendered":"Ressourcen"},"content":{"rendered":"<div class=\"lazyblock-mh-hero-banner-NaDeO alignfull alignfull  wp-block-lazyblock-mh-hero-banner\"><!-- Hero Banner -->\r\n<div class=\"mh-hero-banner  dm-lazyblock-mh-hero-banner-NaDeO\" style=\"background:url(https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/Resources_Hero.jpg) center center no-repeat; background-size: cover;\">\r\n        <div class=\"mh-hero-content\">\r\n            <div class=\"mh-hero-content-block-1\">\r\n              <span class=\"block-1-wrap\">\r\n                <div class=\"mh-hero-heading\">\r\n                        <h1>                            Ressourcen                            <br>St\u00f6bern Sie in unseren Materialien                            <br>f\u00fcr zus\u00e4tzliche Informationen                        \r\n                        <\/h1>\r\n                    <\/div>\r\n                \r\n                        <div class=\"mh-hero-links\"><a class=\"tileButton\" href=\"http:\/\/molecularhealth.com\/eu\/de\/kontakt\/\" target=\"_self\"><i data-feather=\"arrow-right\"><\/i> <span>Kontaktieren Sie uns<\/span><\/a><\/div>              <\/span>\r\n            <\/div>\r\n\r\n            \r\n        <\/div>\r\n<\/div>\r\n<\/div>\n\n\n<p>Im Folgenden finden Sie eine durchsuchbare und filterbare Liste unserer Nachrichten, Pressemitteilungen, Whitepaper, Artikel, wissenschaftlichen Poster und vieles mehr. <br>Wenn Sie etwas nicht finden k\u00f6nnen, <a href=\"http:\/\/molecularhealth.com\/eu\/de\/kontakt\/\" data-type=\"page\" data-id=\"72\">lassen Sie es uns bitte wissen<\/a>, und wir werden uns so schnell wie m\u00f6glich mit Ihnen in Verbindung setzen.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:75%\"><div class=\"lazyblock-mh-resources-posts-2iq12l wp-block-lazyblock-mh-resources-posts\"><div class=\"mh-filter-result\">\r\n    \r\n            <ul class=\"project-tiles\">\r\n            <li><h4>MH Connector<\/h4><div class=\"subline\">MH Connector \u2013 Ihr Schritt hin zu einem end-to-end, multimodalen Daten-Workflow innerhalb Ihres bestehenden NGS-Tumorprofilings<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-25-019-1_MH_Connector_Flyer.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>Dataome-powered Precision Medicine<\/h4><div class=\"subline\">the bioRN Life Science Cluster magazine &#8211; The Heidelberg Ecosystem has it all (MH&#8217;s Beitrag auf Seite 8)<\/div><span><a href=\"https:\/\/issuu.com\/biocom\/docs\/eb_2025_autumn_biorn_life_2025?fr=sNTI4OTgzNTg2MzQ\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions<\/h4><div class=\"subline\">Winter, M et al. Cancers 2026<\/div><span><a href=\"https:\/\/doi.org\/10.3390\/cancers18020216\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Malignant Melanoma: Landscape of Molecular Markers<\/h4><div class=\"subline\">Winter, M. et al. Biomedicines 2026<\/div><span><a href=\"https:\/\/doi.org\/10.3390\/biomedicines14010157\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-and-axxam-enter-into-a-strategic-partnership-to-bolster-the-discovery-of-innovative-targets-in-drug-development\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>MH Guide \u2013 Entdecken Sie die Vorteile der automatisierten klinischen Varianteninterpretation f\u00fcr das molekulare Tumorprofiling<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-23-019-3EN_MH_Guide_Pathology.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>IVDR-konformes molekulares Tumorprofiling \u2013 Die Terti\u00e4ranalyse mit MH Guide<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-24-031-1DE_MH_Guide_IVDR_Flyer.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>MH Guide \u2013 integrierte Datensicherheit und Datenschutz<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-24-003-1_MH_Guide_Data_Security_and_Privacy.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>MH Guide f\u00fcr erbliche Tumorerkrankungen \u2013 Entdecken Sie die Vorteile der automatisierten klinischen Varianteninterpretation f\u00fcr die Analyse erblicher Krebserkrankungen<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-24-008-1EN_MH_Guide_hereditary_cancer.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>MH Guide\/Mendel \u2013 NGS-Terti\u00e4ranalyse f\u00fcr erbliche Tumorerkrankungen und genetische Erkrankungen<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-24-040-1_MH_Guide_Mendel_brochure.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>MH Studienbrosch\u00fcre 2009 &#8211; 2026<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/wp-content\/uploads\/sites\/2\/MH-24-001-4_MH_Study_Brochure.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte<\/h4><div class=\"subline\">Tsibulak, Irina et al. International Journal of Gynecological Cancer. 2025;  35(2):100054. doi: 10.1016\/j.ijgc.2024.100054<\/div><span><a href=\"https:\/\/www.international-journal-of-gynecological-cancer.com\/article\/S1048-891X(24)04617-6\/fulltext\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach<\/h4><div class=\"subline\">Mustea A et al. Cancer Res Clin Oncol. 2024; 150(7):367. https:\/\/doi.org\/10.1007\/s00432-024-05901-4<\/div><span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05901-4\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Integrated DNA Technologies and Molecular Health Ink Commercial Partnership<\/h4><div class=\"subline\">Strategic partnership enables companies to combine technology offerings and streamline NGS workflows <\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/integrated-dna-technologies-and-molecular-health-ink-commercial-partnership\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC<\/h4><div class=\"subline\">Schell, MJ et al. Nat Commun. 2016; 7:11743. doi: 10.1038\/ncomms11743<\/div><span><a href=\"https:\/\/www.nature.com\/articles\/ncomms11743\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer<\/h4><div class=\"subline\">Malgerud, L. et al. Mol Oncol. 2017; 11(10):1413-1429. doi: 10.1002\/1878-0261.12108<\/div><span><a href=\"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.12108\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Consolidated BRCA1\/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide<\/h4><div class=\"subline\">Hirotsu, Y. et al. Int J Mol Sci. 2020; 21(11):3895. doi: 10.3390\/ijms21113895<\/div><span><a href=\"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/3895\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>St. Marianna University School of Medicine in Japan relies on MH Guide for personalized cancer medicine<\/h4><div class=\"subline\">Press release, October 27, 2023<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/st-marianna-university-school-of-medicine-in-japan-relies-on-mh-guide-for-personalized-cancermedicine\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molecular Health and Takara Bio collaborate to support Genome Medicine in Japan<\/h4><div class=\"subline\">Press release, October 13, 2023<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-and-takara-bio-collaborate-to-support-genome-medicine-in-japan\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer \u2013 A Feasibility Study<\/h4><div class=\"subline\">Jaeger, BAS. Geburtshilfe Frauenheilkd. 2023; 83(9):1138-1147. doi: 10.1055\/a-2150-9440<\/div><span><a href=\"https:\/\/www.thieme-connect.com\/products\/ejournals\/abstract\/10.1055\/a-2150-9440\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Analysis and Clinical Relevance of Tumor Mutational Burden<\/h4><div class=\"subline\">Eine Darstellung von TMB als potenzieller Biomarker.<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/analysis-and-clinical-relevance-of-tumor-mutational-burden\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)<\/h4><div class=\"subline\">Jackson, D.B. et al. Pharmaceutics. 2023; 15(6):1673. doi: 10.3390\/pharmaceutics15061673<\/div><span><a href=\"https:\/\/doi.org\/10.3390\/pharmaceutics15061673\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide<\/h4><div class=\"subline\">Mustea, A. et al. Cancers. 2023; 15(7):2053. doi: 10.3390\/cancers15072053<\/div><span><a href=\"https:\/\/doi.org\/10.3390\/cancers15072053\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Derzeit keine Stellenanzeigen<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/derzeit-keine-stellenanzeigen\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Allgemeine Gesch\u00e4ftsbedingungen f\u00fcr MH Guide<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/allgemeine-geschaeftsbedingungen-fuer-mh-guide\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms<\/h4><div class=\"subline\">Brock, S. et al. Front. Mol. Med. 2023; 2:1035290. https:\/\/doi.org\/10.3389\/fmmed.2022.1035290<\/div><span><a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2022.1035290\/full\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Daten t\u00f6ten. Den Krebs.<\/h4><div class=\"subline\">Ein Artikel von Friedrich von Bohlen in der Zeitschrift FOCUS Die Welt in 2023<\/div><span><a href=\"https:\/\/molecularhealth.com\/wp-content\/uploads\/sites\/2\/Focus2023_FVB_article.pdf\" target=\"_blank\" download>Artikel herunterladen<\/a><\/span><\/li><li><h4>Molecular Health erh\u00e4lt IVDR-Zertifikat f\u00fcr MH Guide<\/h4><div class=\"subline\">Pressemitteilung, 13. Juli 2022<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-erhaelt-ivdr-zertifikat-fuer-mh-guide\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Advancing drug safety science by integrating molecular knowledge with post\u2010marketing adverse event reports<\/h4><div class=\"subline\">Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022; 11(5):540-555. doi: 10.1002\/psp4.12765<\/div><span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35143713\/\" target=\"_self\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics<\/h4><div class=\"subline\">Heydt, C. et al. J. Mol. Pathol. 2022; 3(1), 53-67; https:\/\/doi.org\/10.3390\/jmp3010006<\/div><span><a href=\"https:\/\/www.mdpi.com\/2673-5261\/3\/1\/6\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors<\/h4><div class=\"subline\">Kim, S. et al. Clin Transl Sci. 2022; 15(6):1430-1438. doi: 10.1111\/cts.13254   <\/div><span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35191192\/\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>The COVID-19 explorer \u2013 An integrated, whole patient knowledge model of COVID-19 disease<\/h4><div class=\"subline\">Brock, S. et al. Front. Mol. Med. 2022; 2:1035215. https:\/\/doi.org\/10.3389\/fmmed.2022.1035215<\/div><span><a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2022.1035215\/full\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Molekulares Management des Mammakarzinoms: testen, analysieren, besprechen<\/h4><div class=\"subline\"><\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molekulares-management-des-mammakarzinoms-testen-analysieren-besprechen\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Analyse-Software MH Guide unterst\u00fctzt Entscheidungsfindung im Molekularen Tumorboard<\/h4><div class=\"subline\">Pressemitteilung, 25. November 2021<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/analyse-software-mh-guide-unterstuetzt-entscheidungsfindung-im-molekularen-tumorboard\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molecular Health und Gen Era Diagnostics beschlie\u00dfen Zusammenarbeit im Bereich Pr\u00e4zisionsonkologie f\u00fcr die T\u00fcrkei<\/h4><div class=\"subline\">Pressemitteilung, 19. Oktober 2021 <\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-und-gen-era-diagnostics-beschliessen-zusammenarbeit-im-bereich-praezisionsonkologie-fuer-die-tuerkei\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molecular Health und Universit\u00e4tsmedizin Essen starten Verbundprojekt zur besseren Versorgung von COVID-19-Erkrankten<\/h4><div class=\"subline\">Pressemitteilung, 9. August 2021<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-und-universitaetsmedizin-essen-starten-verbundprojekt-zur-besseren-versorgung-von-covid-19-erkrankten\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Konyang Universit\u00e4tsklinikum in S\u00fcdkorea setzt f\u00fcr personalisierte Krebsmedizin auf MH Guide<\/h4><div class=\"subline\">Pressemitteilung, 16. Juli 2021<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/konyang-universitaetsklinikum-in-suedkorea-setzt-fuer-personalisierte-krebsmedizin-auf-mh-guide\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Wir bringen die biologische Grammatik in die Medizin<\/h4><div class=\"subline\">Plattform Life Sciences &#8222;Smarte Medizin&#8220; \u2013 Interview mit Friedrich von Bohlen<\/div><span><a href=\"https:\/\/www.goingpublic.de\/wp-content\/uploads\/epaper\/2021_2_LS\/#10\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Target adverse event profiles for predictive safety in the postmarket setting<\/h4><div class=\"subline\">Peter Schotland, Rebecca Racz, David B. Jackson, Theodoros G. Soldatos, Robert Levin, David G. Strauss and Keith Burkhart. Clinical Pharmacology &amp; Therapeutics. 2021; 109(5):1232-1243. doi: 10.1002\/cpt.2074<\/div><span><a href=\"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2074\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>MH Guide: Molekulare Tumordiagnostik in 7 Schritten<\/h4><div class=\"subline\">Ein \u00dcberblick \u00fcber den MH-Guide-Arbeitsablauf vom Hotspot zum Genprofil<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/mh-guide-molekulare-tumordiagnostik-in-7-schritten\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Panel-Diagnostik statt Hot-Spot? Das sind die Unterschiede<\/h4><div class=\"subline\">Ein \u00dcberblick \u00fcber die Vor- und Nachteile der Verwendung von NGS-basierten Panels f\u00fcr die molekulare Tumorprofilierung<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/panel-diagnostik-statt-hot-spot-das-sind-die-unterschiede\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molecular Health \u2013 intelligente L\u00f6sungen f\u00fcr smarte Medizin<\/h4><div class=\"subline\">NATURE BiopharmaDealmakers<\/div><span><a href=\"https:\/\/www.nature.com\/articles\/d43747-021-00030-0\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>70-J\u00e4hrige mit rezidiviertem Ovarialkarzinom<\/h4><div class=\"subline\">Die Geschichte einer neuen Hoffnung f\u00fcr eine Patientin mit Eierstockkrebs<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/70-jaehrige-mit-rezidiviertem-ovarialkarzinom\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>6 Fragen &amp; Antworten zu MH Guide<\/h4><div class=\"subline\">Eine Liste mit Antworten auf h\u00e4ufig gestellte Fragen zu Terti\u00e4ranalyse-L\u00f6sungen wie MH Guide.<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/6-fragen-antworten-zu-mh-guide\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>HRD: Warum eine BRCA1\/2-Mutationstestung nicht ausreicht<\/h4><div class=\"subline\">Eine \u00dcbersicht kl\u00e4rt drei Fragen zur homologe Rekombinationsdefizienz (HRD)<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/hrd-warum-eine-brca1-2-mutationstestung-nicht-ausreicht\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molecular Health und FALCO biosystems arbeiten zusammen, um genetische Analysen mit MH Guide\/BRCA und MH Guide\/Mendel anzubieten<\/h4><div class=\"subline\">Pressemitteilung, 2. M\u00e4rz 2021<\/div><span><a href=\"https:\/\/molecularhealth.com\/eu\/de\/molecular-health-und-falco-biosystems-arbeiten-zusammen-um-genetische-analysen-mit-mh-guide-brca-und-mh-guide-mendel-anzubieten\/\" target=\"_self\">Weiterlesen<\/a><\/span><\/li><li><h4>Molekulare Diagnostik beim Mammakarzinom \u2013 Wo stehen wir auf dem Weg zur molekular stratifizierten Therapie?<\/h4><div class=\"subline\">\u00c4rzteZeitung \u2013 SpringerMedizin (in German)<\/div><span><a href=\"https:\/\/www.aerztezeitung.de\/Nachrichten\/Wo-stehen-wir-auf-dem-Weg-zur-molekular-stratifizierten-Therapie-417742.html\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Datenprojekt zu Covid-Langzeitfolgen startet<\/h4><div class=\"subline\">Handelsblatt (in German)<\/div><span><a href=\"https:\/\/www.handelsblatt.com\/inside\/digital_health\/friedrich-von-bohlen-datenprojekt-zu-covid-langzeitfolgen-startet\/26948880.html\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>Wie der MH Corona Explorer die Versorgung COVID-19-Kranker verbessern soll<\/h4><div class=\"subline\">\u00c4rzteZeitung (in German)<\/div><span><a href=\"https:\/\/www.aerztezeitung.de\/Medizin\/Wie-der-MH-Corona-Explorer-die-Versorgung-COVID-19-Kranker-verbessern-soll-417310.html\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li><li><h4>A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development<\/h4><div class=\"subline\">Kim, S. et al. Clin Transl Sci. 2022; 15(4):1003-1013. doi: 10.1111\/cts.13219   <\/div><span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35014203\/\" target=\"_blank\">Quelle \u00f6ffnen<\/a><\/span><\/li>        <\/ul>\r\n            \r\n<\/div><\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Im Folgenden finden Sie eine durchsuchbare und filterbare Liste unserer Nachrichten, Pressemitteilungen, Whitepaper, Artikel, wissenschaftlichen Poster und vieles mehr. Wenn Sie etwas nicht finden k\u00f6nnen, lassen Sie es uns bitte wissen, und wir werden uns so schnell wie m\u00f6glich mit Ihnen in Verbindung setzen.<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":6000,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"class_list":["post-1214","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/pages\/1214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/comments?post=1214"}],"version-history":[{"count":28,"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/pages\/1214\/revisions"}],"predecessor-version":[{"id":4375,"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/pages\/1214\/revisions\/4375"}],"wp:attachment":[{"href":"https:\/\/molecularhealth.com\/eu\/de\/wp-json\/wp\/v2\/media?parent=1214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}